Vertex Pharmaceuticals/$VRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Employees
6,100
Headquarters
Website
VRTX Metrics
BasicAdvanced
$108B
29.86
$14.07
0.43
-
Price and volume
Market cap
$108B
Beta
0.43
52-week high
$519.68
52-week low
$362.50
Average daily volume
1.6M
Financial strength
Current ratio
2.52
Quick ratio
2
Long term debt to equity
8.893
Total debt to equity
8.893
Interest coverage (TTM)
260.54%
Profitability
EBITDA (TTM)
4,603.8
Gross margin (TTM)
51.03%
Net profit margin (TTM)
31.86%
Operating margin (TTM)
36.96%
Effective tax rate (TTM)
16.84%
Revenue per employee (TTM)
$1,870,000
Management effectiveness
Return on assets (TTM)
12.53%
Return on equity (TTM)
22.77%
Valuation
Price to earnings (TTM)
29.863
Price to revenue (TTM)
9.466
Price to book
6.27
Price to tangible book (TTM)
6.88
Price to free cash flow (TTM)
30.885
Free cash flow yield (TTM)
3.24%
Free cash flow per share (TTM)
13.604
Growth
Revenue change (TTM)
10.46%
Earnings per share change (TTM)
-838.64%
3-year revenue growth (CAGR)
11.00%
10-year revenue growth (CAGR)
33.65%
3-year earnings per share growth (CAGR)
4.38%
10-year earnings per share growth (CAGR)
16.42%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Bulls say / Bears say
The European Union granted approval for Vertex’s next-generation CFTR modulator Alyftrek in July 2025, expanding its addressable cystic fibrosis population across major EU markets and strengthening its CF leadership ahead of Trikafta’s 2037 patent expiry (Reuters).
Vertex topped Q2 2025 estimates with 12% revenue growth to $2.96 billion and adjusted EPS of $4.52, driven by robust demand for its CF franchise and recent launches (Reuters).
The newly launched non-opioid pain therapy Journavx has rapidly gained commercial traction, with nearly 80,000 prescriptions filled since its March debut, demonstrating strong early market adoption (Reuters).
Vertex missed first-quarter 2025 Wall Street expectations, reporting $2.77 billion in revenue versus the $2.85 billion forecast largely due to underwhelming Trikafta sales of $2.53 billion (versus $2.58 billion est.), dragging adjusted EPS to $4.06 versus $4.32 expected (Reuters).
The company halted development of its experimental non-opioid painkiller after a mid-stage trial failed to meet statistical efficacy endpoints, triggering an 11% share sell-off despite overall Q2 beats and highlighting pipeline execution risks (Reuters).
Although JourNavx has achieved 79,763 prescriptions since its early 2025 launch, analysts caution that this uptake remains below internal targets and may limit the therapy’s near-term revenue contribution (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
Business Wire2 weeks ago
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
Business Wire3 weeks ago
Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBC Television4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $108B as of October 29, 2025.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 29.86 as of October 29, 2025.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.